Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28287503 | 0.87 | NFE2L2 (0.37) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28051736 | 0.82 | NFE2L2 (0.38) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL60529 | 0.82 | HPGD (0.41) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7938427 | 0.77 | MAPT (0.46) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6867335 | 0.77 | ALDH1A1 (0.48) | MAOB | |
| SCHEMBL6289878 | 0.75 | ALDH1A1 (0.50) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6293224 | 0.75 | ALDH1A1 (0.50) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6293197 | 0.75 | ALDH1A1 (0.50) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6289927 | 0.75 | ALDH1A1 (0.50) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6290410 | 0.75 | ALDH1A1 (0.50) | NFE2L2ACHESLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1014 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483291-B | Synthesis method of (E) -beta-aryl-beta, gamma-unsaturated ester compound | 安阳师范学院 | 2021-09-10 | — | — | CN | claimed |
| EP-4747253-A1 | SPIROCYCLIC WRN HELICASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4709711-A1 | ISOQUINOLINONE DERIVATIVES AND 4H-QUINOLIZINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE | Beone Medicines I GmbH (CH) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-20260027089-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-01-01 | — | — | US | disclosed |
| WO-2000066570-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000055161-A1 | 6-SUBSTITUTED BIARYL PURINE DERIVATIVES AS POTENT CYCLIN/CDK INHIBITORS AND ANTIPROLIFERATIVE AGENTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| WO-2000028331-A1 | USE OF RADIOLIGANDS TO SCREEN INHIBITORS OF AMYLOID-BETA PEPTIDE PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000007995-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999062899-A1 | TETRAHYDROINDOLONE DERIVATIVES AS GABAAALPHA5 LIGANDS FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-09 | — | — | WO | disclosed |
| EP-0946511-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-10-06 | — | — | EP | disclosed |
| EP-0915875-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998028275-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998004559-A2 | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027089-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | NFE2L2 2356/4885ACHE 3913/4885SLC6A2 1448/4885 |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | PIK3R4, PIK3R1, PIK3R5 | NFE2L2 2899/4885ACHE 4828/4885SLC6A2 1958/4885 |
| US-20260001843-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPBWR1 | NFE2L2 2967/4885ACHE 3119/4885SLC6A2 332/4885 |
| US-12624028-B2 | 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) | SERPINA2, SERPINC1, SERPINH1 | NFE2L2 975/4885ACHE 3990/4885SLC6A2 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.